Cargando…
Risk factors for Coronavirus disease-associated mucormycosis
BACKGROUND: The epidemiology of the Coronavirus-disease associated mucormycosis (CAM) syndemic is poorly elucidated. We aimed to identify risk factors that may explain the burden of cases and help develop preventive strategies. METHODS: We performed a case-control study comparing cases diagnosed wit...
Autores principales: | Arora, Umang, Priyadarshi, Megha, Katiyar, Varidh, Soneja, Manish, Garg, Prerna, Gupta, Ishan, Bharadiya, Vishwesh, Berry, Parul, Ghosh, Tamoghna, Patel, Lajjaben, Sarda, Radhika, Garg, Shreya, Agarwal, Shubham, Arora, Veronica, Ramprasad, Aishwarya, Kumar, Amit, Garg, Rohit Kumar, Kodan, Parul, Nischal, Neeraj, Singh, Gagandeep, Jorwal, Pankaj, Kumar, Arvind, Baitha, Upendra, Meena, Ved Prakash, Ray, Animesh, Sethi, Prayas, Xess, Immaculata, Vikram, Naval, Sinha, Sanjeev, Biswas, Ashutosh, Thakar, Alok, Bhatnagar, Sushma, Trikha, Anjan, Wig, Naveet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8717704/ https://www.ncbi.nlm.nih.gov/pubmed/34974056 http://dx.doi.org/10.1016/j.jinf.2021.12.039 |
Ejemplares similares
-
Diagnostic Evaluation of Non-Interpretable Results Associated with rpoB Gene in Genotype MTBDRplus Ver 2.0
por: Singh, Binit Kumar, et al.
Publicado: (2020) -
Outcomes associated with standardized treatment regimens for extensively drug-resistant tuberculosis
por: Aggarwal, Anivita, et al.
Publicado: (2020) -
Is there antibody-dependent enhancement in SARS Coronavirus 2?
por: Kumar, Rohit, et al.
Publicado: (2020) -
Battling COVID-19: using old weapons for a new enemy
por: Kumar, Rohit, et al.
Publicado: (2020) -
Outcomes of HFNC Use in COVID-19 Patients in Non-ICU Settings: A Single-center Experience
por: Aggarwal, Anivita, et al.
Publicado: (2022)